Canonical: https://ownershiptrace.com/13f/companies/880

# Who owns ARROWHEAD PHARMACEUTICALS, INC. (ARWR)? Elite investor 13F holders

5 tracked elite investors reported holding ARROWHEAD PHARMACEUTICALS, INC as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC, Oaktree Capital Management, Gotham Asset Management, Polen Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

5 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3,…

## Reported holders and securities, including exits (up to 20)

| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|  --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| [D.E. Shaw](https://ownershiptrace.com/13f/investors/98) | ARROWHEAD PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 35176456.00 USD | 431560.000000 | Shares | reduce | [Original filing](https://www.sec.gov/Archives/edgar/data/1009207/0001104659-26-097217-index.html) |
| [Renaissance Technologies LLC](https://ownershiptrace.com/13f/investors/63) | ARROWHEAD PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 38221751.00 USD | 468921.000000 | Shares | reduce | [Original filing](https://www.sec.gov/Archives/edgar/data/1037389/0001037389-26-000059-index.html) |
| [Oaktree Capital Management](https://ownershiptrace.com/13f/investors/44) | ARROWHEAD PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 10951820.00 USD | 9146000.000000 | Principal | buy | [Original filing](https://www.sec.gov/Archives/edgar/data/949509/0000949509-26-000005-index.html) |
| [Bridgewater Associates](https://ownershiptrace.com/13f/investors/8) | ARROWHEAD PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | [Original filing](https://www.sec.gov/Archives/edgar/data/1350694/0001350694-26-000003-index.html) |
| [Gotham Asset Management](https://ownershiptrace.com/13f/investors/94672) | ARROWHEAD PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 545791.00 USD | 6696.000000 | Shares | reduce | [Original filing](https://www.sec.gov/Archives/edgar/data/1510387/0001398344-26-014644-index.html) |
| [Polen Capital Management](https://ownershiptrace.com/13f/investors/61) | ARROWHEAD PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-04 00:00:00 | 538944.00 USD | 6612.000000 | Shares | buy | [Original filing](https://www.sec.gov/Archives/edgar/data/1034524/0001172661-26-003035-index.html) |

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

[How to read the data](https://ownershiptrace.com/docs#reading-the-data) · [Disclaimer](https://ownershiptrace.com/disclaimer)